Novo Nordisk is investing more than €400 million to expand its manufacturing facility in Athlone, Ireland.
The investment will support the upgrade and retrofit of the existing facility and enhance Novo Nordisk’s capacity to manufacture oral GLP-1s outside the US, the company said.
The work targets the site’s production capabilities for oral GLP-1 medicines, the Wegovy pills.
The investment aims to increase manufacturing capacity of the so-called wonder weightloss drug beyond the United States, bolstering global supply of this version, which doesn't involve injections.
It said the funding would support facility upgrades and retrofits to enable higher-volume production of oral GLP-1s at the Athlone site, in the Irish midlands.
The recap
Novo Nordisk is investing more than €400 million in Athlone.
Investment will expand capacity to make oral GLP-1s outside US.
Funds will support upgrade and retrofit of the existing facility.